11/10/2026 updated
CH
100 % available
CMO/SVP Clinical Development & Regulatory Affairs | Entrepreneurial C-Level Executive | M.D.
Menlo Park, USA
Worldwide
M.B., B.S. - Middlesex Hospital Medical School, University of LondonAbout me
Entrepreneurial C-level executive. Over 38 years pharma experience: pre-IND to Phase IV across a broad range of therapeutic areas. Secured over $450MM in financing including IPO. In- and out-license diligence. Filed and prosecuted multiple NDAs/MAAs. Prix Galien nominee 2022 Zokinvy®
Clinical Development Strategy
Expertise spanning all phases of drug development from pre-IND to Phase IV post-marketing support, including design and implementation of clinical development programs across a broad range of therapeutic areas such as rare diseases, cardiovascular, infectious diseases, and autoimmune conditions.
Regulatory Affairs & NDA/MAA Submissions
Extensive track record in filing and prosecuting multiple NDAs for NCEs, including the successful NDA and MAA approval of lonafarnib (Zokinvy) for Hutchinson-Gilford Progeria Syndrome. Leadership of global regulatory interactions with FDA, EMA, PMDA, and other agencies.
Venture Capital Fundraising & Investor Relations
Proven ability to secure significant financing in start-up and growth-stage pharmaceutical environments, having raised over $450 million in venture capital, private and public financing including IPO participation and follow-on offerings.
CRO Management & Outsourcing
Extensive experience in CRO selection, contract negotiation, scope definition, and management of clinical development plans through CRO partnerships, including budget, manpower, and timeline oversight.
Portfolio & Program Management
Portfolio management for NCE development including departmental budget management, manpower planning, and oversight of multi-function matrix project teams across large-scale international programs.
In-License & Out-License Diligence
Hands-on experience in in-license and out-license diligence activities, including negotiation of out-license partnerships and business development evaluation of M&A, licensing, and partnership opportunities.
Medical & Scientific Leadership
Clinical and scientific leadership of pharmaceutical organizations, including line management of MDs, supervisory responsibilities for Clinical Development organizations, and establishment of scientific and clinical advisory boards.
Integrated Non-Clinical/Clinical Strategy
Definition of integrated non-clinical and clinical strategies for drug development programs, covering development of both small and large molecules from pre-IND through to marketing approval.
Therapeutic Area Expertise
Broad therapeutic area experience including ultra-rare genetic pediatric disease, cardiovascular disease, infectious diseases, autoimmune disease, endocrine diseases, renal disease, CNS disease, cystic fibrosis, and growth hormone deficiency.
Expertise spanning all phases of drug development from pre-IND to Phase IV post-marketing support, including design and implementation of clinical development programs across a broad range of therapeutic areas such as rare diseases, cardiovascular, infectious diseases, and autoimmune conditions.
Regulatory Affairs & NDA/MAA Submissions
Extensive track record in filing and prosecuting multiple NDAs for NCEs, including the successful NDA and MAA approval of lonafarnib (Zokinvy) for Hutchinson-Gilford Progeria Syndrome. Leadership of global regulatory interactions with FDA, EMA, PMDA, and other agencies.
Venture Capital Fundraising & Investor Relations
Proven ability to secure significant financing in start-up and growth-stage pharmaceutical environments, having raised over $450 million in venture capital, private and public financing including IPO participation and follow-on offerings.
CRO Management & Outsourcing
Extensive experience in CRO selection, contract negotiation, scope definition, and management of clinical development plans through CRO partnerships, including budget, manpower, and timeline oversight.
Portfolio & Program Management
Portfolio management for NCE development including departmental budget management, manpower planning, and oversight of multi-function matrix project teams across large-scale international programs.
In-License & Out-License Diligence
Hands-on experience in in-license and out-license diligence activities, including negotiation of out-license partnerships and business development evaluation of M&A, licensing, and partnership opportunities.
Medical & Scientific Leadership
Clinical and scientific leadership of pharmaceutical organizations, including line management of MDs, supervisory responsibilities for Clinical Development organizations, and establishment of scientific and clinical advisory boards.
Integrated Non-Clinical/Clinical Strategy
Definition of integrated non-clinical and clinical strategies for drug development programs, covering development of both small and large molecules from pre-IND through to marketing approval.
Therapeutic Area Expertise
Broad therapeutic area experience including ultra-rare genetic pediatric disease, cardiovascular disease, infectious diseases, autoimmune disease, endocrine diseases, renal disease, CNS disease, cystic fibrosis, and growth hormone deficiency.
Experience
Professional experience10+ years
Freelancer since2018
Languages
EnglishNative speaker
Project history
Development strategy, design and implementation of clinical development programs, regulatory strategy, and member of Management Team. Working with a fusion protein in the field of muscle regeneration, advancing from pre-IND/IND to Phase 1 FIH studies and onto a Phase 1/2a mechanistic PoC study.
Operational and strategic drug development consulting services to the pharmaceutical industry. Clients include EIT Pharma (2024-present), Trellis Biosciences (2018-present), and Sentynl Therapeutics (2024-present).
Founder of an immuno-oncology biotech start-up company, now dormant.